Kaya Holdings, Inc.
KAYSAbout the company
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, operates psychedelic treatment clinics and medical cannabis dispensaries in the United States. It produces, distributes, and sells a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages; and provides medical and recreational cannabis, and cannabidiol products.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
2 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 16 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Annual history · FY 2024 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14 | Annual history · FY 2024 · Balance sheet at 2025-09-30 · TTM ended 2025-09-30 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14 | Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-11-01 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment · Balance sheet at 2025-09-30 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-29 Score computed: 2026-11-14 | Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-11-01 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2025-09-30 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-29 Score computed: 2026-11-14 | TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2024 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-29 Score computed: 2026-11-14 | Annual history · FY 2024 · Balance sheet at 2025-09-30 Latest source filing: 2025-11-20 Score computed: 2026-11-14 | TTM ended 2025-09-30 · Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-11-20 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 3✗ 32▾
No clean pass — all 16 investors flag at least one profitability criterion
Positive EPS (10 years)4/18 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)4/18 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-28343.5% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-2.1M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROEN/A (negative equity)✗Lynch> 15%EBIT / Enterprise Value-183.4%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-183.4%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-961.72%✗PiotroskiROA > 0ROA Change YoY745.73% -> -961.72% (delta: -1707.44%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-383.98%, ROA=-961.72%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY58.6% -> -5.1%✗PiotroskiImproved YoYPre-Tax Income / Revenue887423.5%✓Dreman>= 8%Net Income / Shareholders' Equity✗Dreman> 12%Margin of Safety✗PabraiP/B < 1.5 or P/E < 15Return on Equity✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency4/17 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue70177.7%✓Ackman>= 15%Net Income / Shareholders Equity✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-249.7% (2022) -> -28343.5% (2024)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 67.2% -> -5.1%, operating margin -249.7% -> -28343.5%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-1315.89%; #6102/6340 (top 96.2%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets-3.45%; #3600/3702 (top 97.2%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-6.7371; #5660/5884 (top 96.2%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR0.0% over 5 years✗Neff7%-20% annualizedPositive Diluted-EPS Years3/8 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Valuation0% pass✗ 28▾
All 13 investors flag KAYS's valuation
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-183.4%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-183.4%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per ShareN/A (negative BVPS)✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-3895.0%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-96.1%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical Average✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low1300% of trailing low ($0.00)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-1315.89%; #6102/6340 (top 96.2%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization-0.6135; #5974/6449 (top 92.6%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization-0.0015; #5235/5247 (top 99.8%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-96.14%; #4060/4519 (top 89.8%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-96.15%; #6075/6202 (top 98.0%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-2.1M✗BuffettPositive and growingFCF Positive and Growing$-0.9M✗LynchPositive and growingOperating Cash Flow$-0.8M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-383.98%, ROA=-961.72%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-96.1%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/11 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-1589.7%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/14 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-0.9M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-96.14%; #4060/4519 (top 89.8%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -99.0% vs Rev: -96.4%✓LynchInventory growth < Revenue growthEPS Growth Direction$-0.07 (2011) -> $-0.07 (2024)✗DremanPositive over recent yearsEPS CAGR0.0% CAGR over 10 years✗Dreman> 5% annualizedPositive Net Income Frequency4/17 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-71.4%✗Ackman>= 5%Positive EPS Growth Frequency0/2 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 67.2% -> -5.1%, operating margin -249.7% -> -28343.5%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR-62.9%✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR0.0% over 5 years✗Neff7%-20% annualized - Efficiency0% pass✓ 1✗ 10▾
No clean pass — all 8 investors flag at least one efficiency criterion
Current Ratio0.04✗Graham>= 2.0ROIC (3-5 yr avg)✗Buffett> 10%ROIC - WACC✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)✗Greenblatt> 25%Current Ratio Change YoY0.01 -> 0.01✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.91x -> 0.03x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities0.04✗Dreman> 1.5Return on Invested CapitalN/A (non-positive invested capital)✗Munger> 15%ROIC (high and growing)FY2022: ROIC=unavailable; FY2023: ROIC=unavailable; FY2024: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)✗SleepROIC > 12% in a majority of years - Verdicts7% pass✓ 1✗ 13▾
Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 4)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (1/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage8% pass✓ 1✗ 14▾
11 of 12 flag KAYS's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -34.2x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / EquityN/A (negative equity)✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.04✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt LevelsN/A (non-positive equity)✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-34.2x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2024
Share retirement not available for this company.
- Buybacks
- $18.0K
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2025-09-30 2024-10-01 – 2025-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex. | Q3 FY 2025 2025-07-01 – 2025-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization. | Q2 FY 2025 2025-04-01 – 2025-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization. | Q1 FY 2025 2025-01-01 – 2025-03-31 Sources | FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
| FY 2020Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $892.4Kcurrent | -- | -- | -- | $1.5Mest. | $8.1Mest. | $1.6Mest. | -- | $6.2Mest. |
| Revenue | -$1.3K | $5.4K↑80% | $10.1K | $7.1K↓75% | $7.1K↓96% | $196.3K↓71% | $685.4K↓23% | $889.9K↓14% | $1.0M |
| Operating Income | -$924.9K | -$269.0K↑76% | -$162.6K | -$309.5K↓4% | -$2.0M↓98% | -$1.0M↑40% | -$1.7M↓20% | -$1.4M↑22% | -$1.8M |
| Net Income | -$11.7M | -$8.6M↓249% | -$2.6M | -$1.6M↓51% | -$2.1M↓229% | $1.6M↑145% | -$3.6M↓137% | $9.7M↑179% | -$12.3M |
| EPS (Diluted) | -- | $-0.06↑40% | $-0.06 | $-0.04 | $-0.07↓800% | $0.01 | -- | -- | $-0.92 |
| Gross Margin | 522.2% | 99.3%↑9% | 33.3% | 29.5%↓43% | -5.1%↓109% | 58.6%↓13% | 67.2%↓2% | 68.6%↓2% | 69.8% |
| Operating Margin | 70177.7% | -4974.3%↑87% | -1610.2% | -4389.4%↓312% | -28343.5%↓5340% | -521.0%↓109% | -249.7%↓55% | -160.7%↑10% | -178.2% |
| ROE | 2145.0% | — | — | — | 13.8%↑219% | -11.7%↓157% | 20.3%↑130% | -67.5%↓228% | 52.5% |
| Total Debt | $445.1K | $445.1K↑78% | $250.0K | $250.0K | $250.0K | $250.0K | $250.0K | $250.0K↓96% | $6.4M |
| Shareholders' Equity | -$547.4K | -$547.4K↑97% | -$19.1M | -$16.7M↑1% | -$15.0M↓9% | -$13.8M↑22% | -$17.6M↓22% | -$14.4M↑38% | -$23.4M |
| Current Ratio | 0.04 | 0.04↑338% | 0.01 | 0.01↓49% | 0.01↑1% | 0.01↑133% | 0.01↓93% | 0.08↑1440% | 0.01 |
| Debt / Equity | -0.81 | -0.81↓5136% | -0.01 | -0.02↓1% | -0.02↑8% | -0.02↓28% | -0.01↑18% | -0.02↑94% | -0.27 |
| Operating Cash Flow | -$567.3K | -$67.7K | -$208.4K | -$183.6K↓3% | -$830.8K↑30% | -$1.2M↓29% | -$918.8K↑12% | -$1.0M↓260% | -$289.6K |
| Free Cash Flow | -- | -- | -- | -- | -$858.0K | -- | -- | -$1.1M | -- |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
KAYS vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |